Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a foaming antacid combination medication used for the symptomatic treatment of peptic ulcers, heartburn, acid reflux, and indigestion. The formulation contains aluminum hydroxide gel, magnesium trisilicate, sodium bicarbonate, and alginic acid (alginate). The mechanism of action involves neutralizing gastric acid by increasing the pH of gastric juice through a neutralization reaction. Magnesium trisilicate also precipitates colloidal silica, which coats the gastrointestinal mucosa, providing additional protection. The gelatinous silicon dioxide formed by the reaction with gastric contents protects ulcerated mucosal surfaces and promotes healing. This is classified as a drug combination in the antacids class.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium trisilicate + sodium bicarbonate + aluminium hydroxide.